



## Vanessa Kennedy

Assistant Professor of Medicine (Blood and Marrow Transplantation and Cellular Therapy)

Medicine - Blood & Marrow Transplantation

### CLINICAL OFFICE (PRIMARY)

- **Bone Marrow Transplant**

780 Welch Road CJ250B

Stanford, CA 94305

Tel (650) 724-4155

Fax (650) 725-7850

### Bio

---

#### BIO

Dr. Kennedy is a board-certified hematologist and medical oncologist who specializes in the treatment of myeloid malignancies, including acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), and myelofibrosis (MF). She is an Assistant Professor in the Department of Medicine, Division of Blood and Marrow Transplantation & Cellular Therapy, at Stanford University School of Medicine.

Dr. Kennedy conducts extensive research, ranging from interventional clinical trials to epidemiology studies. She also has expertise in the use of clinical informatics and bioinformatics in improving patient outcomes. Her work has been supported by grant funding from the American Society of Clinical Oncology, the American Society of Hematology, and the Chan-Zuckerberg Foundation. Her goal is to understand and improve outcomes in patients with myeloid malignancies.

#### CLINICAL FOCUS

- Hematology

#### ACADEMIC APPOINTMENTS

- Assistant Professor - University Medical Line, Medicine - Blood & Marrow Transplantation

#### HONORS AND AWARDS

- Physician-Scientist Fellow, Chan-Zuckerberg Institute (2021 - 2023)
- Editorial Fellow, Journal of Clinical Oncology - Clinical Cancer Informatics (2022 - 2023)
- Young Investigator Award, American Society of Clinical Oncology (2022)
- Abstract Achievement Award, American Society of Hematology (2020)
- Rachel Perline Award, UCSF (2020)
- HONORS Award, American Society of Hematology (2018)
- Abstract Achievement Award, American Society of Hematology (2015)

#### PROFESSIONAL EDUCATION

- Board Certification, American Board of Internal Medicine , Medical Oncology (2023)

- Board Certification: Hematology, American Board of Internal Medicine (2022)
- Fellowship: UCSF Hematology and Medical Oncology Fellowship (2022) CA
- Board Certification: Internal Medicine, American Board of Internal Medicine (2019)
- Residency: Stanford University Internal Medicine Residency (2019) CA
- Medical Education: Vanderbilt University School of Medicine (2016) TN

## Publications

---

### PUBLICATIONS

- **Long-Term Clinical Outcomes and B Cell Immune Reconstitution following Allo-HCT with Prophylactic, Post-Transplant Rituximab.** *Transplantation and cellular therapy*  
Kennedy, V. E., Sahaf, B., Wu, F., Ehlinger, Z. J., Arai, S., Miklos, D. B.  
2024
- **LNK/SH2B3 as a novel driver in juvenile myelomonocytic leukemia.** *Haematologica*  
Wintering, A., Hecht, A., Meyer, J., Wong, E. B., Hübner, J., Abelson, S., Feldman, K., Kennedy, V. E., Peretz, C. A., French, D. L., Maguire, J. A., Jobaliya, C., Vasquez, et al  
2023
- **The FLT3N701K mutation causes clinical AML resistance to gilteritinib and triggers TKI sensitivity switch to quizartinib.** *American journal of hematology*  
Joshi, S. K., Pittsenbarger, J., Kennedy, V. E., Peretz, C. A., Perl, A. E., Smith, C. C., Tyner, J. W., Druker, B. J., Traer, E.  
2023
- **Measurable residual disease conversion rate with consolidation chemotherapy in acute myeloid leukemia.** *Leukemia & lymphoma*  
Gaut, D., Oliai, C., Boiarsky, J., Zhang, S., Salhotra, A., Azenkot, T., Kennedy, V. E., Khanna, V., Olmedo Gutierrez, K., Shukla, N., Moskoff, B., Park, G., Afkhami, et al  
2023: 1-9
- **Daratumumab Plus Bortezomib and Dexamethasone in Newly Diagnosed Systemic Light Chain Amyloidosis.** *Current problems in cancer*  
Kennedy, V. E., Natsuhara, K., Maringanti, S. A., Shah, N. D., Arora, S., Wolf, J., Martin, T. G., Aras, M. A., Chung, A., Wong, S. W.  
2023; 47 (3): 100953
- **Microfluidics-free single-cell genomics with templated emulsification.** *Nature biotechnology*  
Clark, I. C., Fontanez, K. M., Meltzer, R. H., Xue, Y., Hayford, C., May-Zhang, A., D'Amato, C., Osman, A., Zhang, J. Q., Hettige, P., Ishibashi, J. S., Delley, C. L., Weisgerber, et al  
2023
- **Mast Cell Leukemia: Clinical and Molecular Features and Survival Outcomes of Patients in the ECNM Registry.** *Blood advances*  
Kennedy, V. E., Perkins, C., Reiter, A., Jawhar, M., Lubke, J., Kluin-Nelemans, H. C., Shomali, W., Langford, C., Abuel, J., Hermine, O., Niedoszytko, M., Gorska, A., Mital, et al  
2022
- **Geriatric assessment in adults age 50 years and older undergoing autologous hematopoietic cell transplantation for lymphoma.** *Journal of geriatric oncology*  
Kennedy, V. E., Huang, C. Y., Kaplan, L. D., Andreadis, C., Ai, W. Z., Olin, R. L.  
2022; 13 (5): 644-647
- **Infectious complications in patients with relapsed refractory multiple myeloma after BCMA CAR T-cell therapy.** *Blood advances*  
Kambhampati, S., Sheng, Y., Huang, C. Y., Bylsma, S., Lo, M., Kennedy, V., Natsuhara, K., Martin, T., Wolf, J., Shah, N., Wong, S. W.  
2022; 6 (7): 2045-2054
- **Outcomes of Allogeneic Transplantation after Hypomethylating Agents with Venetoclax in Acute Myeloid Leukemia.** *American journal of hematology*  
Kennedy, V. E., Hui, G., Azenkot, T., Gaut, D., Wieduwilt, M. J., Oliai, C., Jonas, B. A., Mittal, V., Logan, A. C., Muffly, L. S., Mannis, G. N.  
2022
- **Characterisation of infections in patients with acute myeloid leukaemia receiving venetoclax and a hypomethylating agent.** *British journal of haematology*  
On, S., Rath, C. G., Lan, M., Wu, B., Lau, K. M., Cheung, E., Alegria, W., Young, R., Tan, M., Kim, C., Phun, J., Patel, N., Mannis, et al

2022

- **Macrophage activation syndrome-like (MAS-L) manifestations following BCMA-directed CAR T cells in multiple myeloma.** *Blood advances*  
Kennedy, V. E., Wong, C., Huang, C. Y., Kambhampati, S., Wolf, J., Martin, T. G., Shah, N., Wong, S. W.  
2021; 5 (23): 5344-5348
- **VITT following Ad26.COV2.S vaccination presenting without radiographically demonstrable thrombosis.** *Blood advances*  
Kennedy, V. E., Wong, C. C., Hong, J. M., Peng, T., Brondfield, S., Reilly, L. M., Cornett, P., Leavitt, A. D.  
2021; 5 (22): 4662-4665
- **Haematopoietic stem-cell transplantation in older adults: geriatric assessment, donor considerations, and optimisation of care.** *The Lancet. Haematology*  
Kennedy, V. E., Olin, R. L.  
2021; 8 (11): e853-e861
- **Frontline treatment patterns and outcomes among older adults with acute myeloid leukemia: A population-based analysis in the modern era.** *Cancer*  
Kennedy, V. E., Keegan, T. H., Li, Q., Maguire, F. B., Muffly, L. S.  
2021
- **Early Time-to-Tocilizumab after B Cell Maturation Antigen-Directed Chimeric Antigen Receptor T Cell Therapy in Myeloma.** *Transplantation and cellular therapy*  
Banerjee, R., Marsal, J., Huang, C. Y., Lo, M., Kambhampati, S., Kennedy, V. E., Arora, S., Wolf, J. L., Martin, T. G., Wong, S. W., Shah, N.  
2021; 27 (6): 477.e1-477.e7
- **A Case of EBV-Negative Aggressive NK-cell Leukemia: Use of Next-Generation Sequencing in Demystifying a Diagnostic Dilemma and Guiding Clinical Care.** *Clinical lymphoma, myeloma & leukemia*  
Kennedy, V. E., Ruiz-Cordero, R., Jangam, D., Wen, K. W., Dunavin, N., Ohgami, R. S., Bhargava, P., Ai, W., Fakhri, B.  
2021
- **Cytogenetic and molecular aberrations and worse outcome for male patients in systemic mastocytosis.** *Theranostics*  
Kluin-Nelemans, H. C., Jawhar, M., Reiter, A., van Anrooij, B., Gotlib, J., Hartmann, K., Illerhaus, A., Oude Elberink, H. N., Gorska, A., Niedoszytko, M., Lange, M., Scaffidi, L., Zanotti, et al  
2021; 11 (1): 292-303
- **FLT3 Mutations in Acute Myeloid Leukemia: Key Concepts and Emerging Controversies.** *Frontiers in oncology*  
Kennedy, V. E., Smith, C. C.  
2020; 10: 612880
- **Marked Hyperbilirubinemia-Silent No More!** *The American journal of medicine*  
Kennedy, V. E., Leavitt, A. D., Cornett, P.  
2020; 133 (12): e733-e734
- **Late Effects in Survivors of Adolescent and Young Adult Acute Lymphoblastic Leukemia.** *JNCI cancer spectrum*  
Muffly, L., Maguire, F. B., Li, Q., Kennedy, V., Keegan, T. H.  
2020; 4 (4): pkaa025
- **MARS: Mutation-Adjusted Risk Score for Advanced Systemic Mastocytosis**  
Jawhar, M., Schwaab, J., Alvarez-Twose, I., Shoumariyeh, K., Naumann, N., Luebke, J., Perkins, C., Munoz-Gonzalez, J. I., Meggendorfer, M., Kennedy, V., Metzgeroth, G., Fabarius, A., Pfeifer, et al  
KARGER.2020: 107-8
- **Prognostic impact of eosinophils in mastocytosis: analysis of 2350 patients collected in the ECNM Registry.** *Leukemia*  
Kluin-Nelemans, H. C., Reiter, A., Illerhaus, A., van Anrooij, B., Hartmann, K., Span, L. F., Gorska, A., Niedoszytko, M., Lange, M., Scaffidi, L., Zanotti, R., Bonadonna, P., Perkins, et al  
2019
- **Immune Reconstitution and Long-Term Outcomes Following Allo-HCT with TLI-ATG and Post-Transplant Rituximab**  
Kennedy, V. E., Arai, S., Miklos, D. B., Wu, F.  
AMER SOC HEMATOLOGY.2019
- **Late Effects and Subsequent Neoplasms in Survivors of Adolescent and Young Adult Acute Lymphoblastic Leukemia: A Population-Based Analysis Including Impact of Front-Line Regimen Type**

- Muffly, L. S., Maguire, F., Li, Q., Kennedy, V., Keegan, T. M.  
AMER SOC HEMATOLOGY.2019
- **Differential Interaction of Peripheral Blood Lymphocyte Counts (ALC) With Different in vivo Depletion Strategies in Predicting Outcomes of Allogeneic Transplant: An International 2 Center Experience** *FRONTIERS IN ONCOLOGY*  
Sheth, V., Kennedy, V., de lavallade, H., Mclornan, D., Potter, V., Engelhardt, B. G., Savani, B., Chinratanalab, W., Goodman, S., Greer, J., Kassim, A., York, S., Kenyon, et al  
2019; 9
  - **Differential Interaction of Peripheral Blood Lymphocyte Counts (ALC) With Different in vivo Depletion Strategies in Predicting Outcomes of Allogeneic Transplant: An International 2 Center Experience.** *Frontiers in oncology*  
Sheth, V., Kennedy, V., de Lavallade, H., Mclornan, D., Potter, V., Engelhardt, B. G., Savani, B., Chinratanalab, W., Goodman, S., Greer, J., Kassim, A., York, S., Kenyon, et al  
2019; 9: 623
  - **Assessment of older adult candidates for allogeneic hematopoietic cell transplantation: updates and remaining questions** *EXPERT REVIEW OF HEMATOLOGY*  
Kennedy, V. E., Muffly, L. S.  
2019; 12 (2): 99-106
  - **Assessment of Older Adult Candidates for Allogeneic Hematopoietic Cell Transplantation: Updates and Remaining Questions.** *Expert review of hematology*  
Kennedy, V. E., Muffly, L. S.  
2019
  - **Nonmyeloablative TLI-ATG conditioning for allogeneic transplantation: mature follow-up from a large single-center cohort.** *Blood advances*  
Spinner, M. A., Kennedy, V. E., Tamaresis, J. S., Lavori, P. W., Arai, S. n., Johnston, L. J., Meyer, E. H., Miklos, D. B., Muffly, L. S., Negrin, R. S., Rezvani, A. R., Shizuru, J. A., Weng, et al  
2019; 3 (16): 2454–64
  - **MARS: Mutation-Adjusted Risk Score for Advanced Systemic Mastocytosis.** *Journal of clinical oncology : official journal of the American Society of Clinical Oncology*  
Jawhar, M. n., Schwaab, J. n., Álvarez-Twose, I. n., Shoumariyeh, K. n., Naumann, N. n., Lübke, J. n., Perkins, C. n., Muñoz-González, J. I., Meggendorfer, M. n., Kennedy, V. n., Metzgeroth, G. n., Fabarius, A. n., Pfeifer, et al  
2019: JCO1900640
  - **Nonmyeloablative Allogeneic Transplantation Using TLI-ATG Conditioning for Lymphoid and Myeloid Malignancies: Mature Follow-up from a Large, Single Institution Cohort**  
Spinner, M. A., Kennedy, V. E., Tamaresis, J. S., Lavori, P. W., Elder, L. V., Arai, S., Johnston, L. J., Meyer, E. H., Miklos, D. B., Muffly, L. S., Negrin, R. S., Rezvani, A. R., Shizuru, et al  
AMER SOC HEMATOLOGY.2018
  - **The Data Registry of the European Competence Network on Mastocytosis (ECNM): Set Up, Projects, and Perspectives.** *The journal of allergy and clinical immunology. In practice*  
Valent, P., Oude Elberink, J. N., Gorska, A., Lange, M., Zanotti, R., van Anrooij, B., Bonifacio, M., Bonadonna, P., Gleixner, K. V., Hadzijusufovic, E., Perkins, C., Hartmann, K., Illerhaus, et al  
2018
  - **Importance of peripheral blood absolute lymphocyte counts (ALC) in predicting transplant outcomes in preparative regimens using anti-thymocyte globulin or alemtuzumab: an international 2 centre experience**  
Sheth, V., Kennedy, V., de Lavallade, H., Mclornan, D., Potter, V., Savani, B., Chinratanalab, W., Engelhardt, B., Goodman, S., Greer, J., Kassim, A., York, S., Kulasekararaj, et al  
NATURE PUBLISHING GROUP.2018: 425–26
  - **Strongyloides Hyperinfection After Immunosuppression in an Immigrant From El Salvador: A Case for Early Diagnosis and Treatment.** *Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases*  
Hoppenfeld, M. S., Kennedy, V., Sheth, K., Chang, A., Nelson, J., Fairchild, R. M.  
2018
  - **Defining the complex phenotype of severe systemic loxoscelism using a large electronic health record cohort** *PLOS ONE*  
Robinson, J. R., Kennedy, V. E., Doss, Y., Bastarache, L., Denny, J., Warner, J. L.  
2017; 12 (4)

- **Allogeneic Hematopoietic Cell Transplantation for Adult T Cell Acute Lymphoblastic Leukemia.** *Biology of blood and marrow transplantation*  
Hamilton, B. K., Rybicki, L., Abounader, D., Adekola, K., Advani, A., Aldoss, I., Bachanova, V., Bashey, A., Brown, S., DeLima, M., Devine, S., Flowers, C. R., Ganguly, et al  
2017
- **Rituximab-containing reduced-intensity conditioning improves progression-free survival following allogeneic transplantation in B cell non-Hodgkin lymphoma.** *Journal of hematology & oncology*  
Epperla, N. n., Ahn, K. W., Ahmed, S. n., Jagasia, M. n., DiGilio, A. n., Devine, S. M., Jaglowski, S. n., Kennedy, V. n., Rezvani, A. R., Smith, S. M., Sureda, A. n., Fenske, T. S., Kharfan-Dabaja, et al  
2017; 10 (1): 117
- **Optimizing Anti-Thymocyte Globulin Dosing for Unrelated Donor Allogeneic Hematopoietic Cell Transplant Based on Recipient Absolute Lymphocyte Count.** *Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation*  
Kennedy, V. E., Chen, H. n., Savani, B. N., Greer, J. n., Kassim, A. A., Engelhardt, B. G., Goodman, S. n., Sengsayadeth, S. n., Chinratanalab, W. n., Jagasia, M. n.  
2017
- **Reduced-Intensity Conditioning with Fludarabine, Cyclophosphamide, and Rituximab Is Associated with Improved Outcomes Compared with Fludarabine and Busulfan after Allogeneic Stem Cell Transplantation for B Cell Malignancies** *BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION*  
Kennedy, V. E., Savani, B. N., Greer, J. P., Kassim, A. A., Engelhardt, B. G., Goodman, S. A., Sengsayadeth, S., Chinratanalab, W., Jagasia, M.  
2016; 22 (10): 1801-1807
- **Does adherence to epilepsy quality measures correlate with reduced epilepsy-related adverse hospitalizations? A retrospective experience** *EPILEPSIA*  
Ladner, T. R., Morgan, C. D., Pomerantz, D. J., Kennedy, V. E., Azar, N., Haas, K., Lagrange, A., Gallagher, M., Singh, P., Abou-Khalil, B. W., Arain, A. M.  
2015; 56 (5): E63-E67
- **Hyaluronan Contributes to Bronchiolitis Obliterans Syndrome and Stimulates Lung Allograft Rejection through Activation of Innate Immunity** *AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE*  
Todd, J. L., Wang, X., Sugimoto, S., Kennedy, V. E., Zhang, H. L., Pavlisko, E. N., Kelly, F. L., Huang, H., Kreisel, D., Palmer, S. M., Gelman, A. E.  
2014; 189 (5): 556-566
- **Bronchoalveolar Lavage as a Tool to Predict, Diagnose and Understand Bronchiolitis Obliterans Syndrome** *AMERICAN JOURNAL OF TRANSPLANTATION*  
KENNEDY, V. E., Todd, J. L., Palmer, S. M.  
2013; 13 (3): 552-561
- **Epithelial clara cell injury occurs in bronchiolitis obliterans syndrome after human lung transplantation.** *American journal of transplantation*  
Kelly, F. L., KENNEDY, V. E., Jain, R., Sindhwani, N. S., Finlen Copeland, C. A., Snyder, L. D., Eu, J. P., Meltzer, E. B., Brockway, B. L., Pavlisko, E., Stripp, B. R., Palmer, S. M.  
2012; 12 (11): 3076-3084